Inactive Instrument

Kiadis Pharma N.V.

Equities

KDS

NL0011323407

Biotechnology & Medical Research

Kiadis Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2020

September 29, 2020

Kiadis Pharma N.V. Announced earnings results for the half year ended June 30, 2020. For the half year, the company announced operating loss was EUR 19.867 million compared to EUR 25.734 million a year ago. Net loss was EUR 18.844 million compared to EUR 25.934 million a year ago. Basic loss per share from continuing operations was EUR 0.57 compared to EUR 1.03 a year ago.

Latest news about Kiadis Pharma N.V.

Sanofi : Delays Privatization of Kiadis on Pending Mandatory Buy-Out	16/07/21	MT
Certain Ordinary Shares of Kiadis Pharma N.V. are subject to a Lock-Up Agreement Ending on 31-MAY-2021.	30/05/21	CI
Kiadis Pharma N.V.(ENXTAM:KDS) dropped from Next Biotech Index	24/05/21	CI
Sanofi : to Delist Kiadis in Amsterdam, Brussels on May 25	29/04/21	MT
Sanofi : to Delist Kiadis from Euronext on May 25	27/04/21	MT
Sanofi : Closes $368 Million Purchase of Kiadis	19/04/21	MT
Kiadis Pharma N.V.(ENXTAM:KDS) dropped from Netherlands ASCX AMS Small Cap Index	14/04/21	CI
Sanofi : Declares Kiadis Offer Unconditional, All Offer Conditions Now Satisfied	13/04/21	MT
Sanofi : Declares Offer for Immunotherapy Company Kiadis Unconditional	13/04/21	MT
Sanofi Foreign Participations B.V. completed the acquisition of Kiadis Pharma N.V. from Life Sciences Partners BV and others.	11/04/21	CI
Kiadis Pharma N : Sanofi's Takeover Offer for Kiadis Receives Commitments from 49% Shareholders	09/04/21	MT
Kiadis Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2020	07/04/21	CI
Kiadis Pharma N.V. Auditor Raises 'Going Concern' Doubt	06/04/21	CI
Sanofi : Kiadis Approves All Resolutions Related To Merger Proposal By Sanofi	30/03/21	MT
Kiadis Pharma N.V.(ENXTAM:KDS) added to Netherlands ASCX AMS Small Cap Index	22/03/21	CI
Sanofi : Launches Kiadis Cash Takeover	12/02/21	MT
Sanofi : Takeover Offer Receives Irrevocable Commitments from Almost 37% of Kiadis Shareholders	03/02/21	MT
Kiadis Pharma N : Takes $24.2 Million From Bridge Loan With Sanofi	14/01/21	MT
Goodwin : Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy	11/01/21	RE
Sanofi : $374 Million Kiadis Takeover Clears Competition Hurdle	09/12/20	MT
Kiadis Pharma N.V. Announces New Data Related to Its K-NK Cell Therapy Platform	12/11/20	CI
Kiadis Pharma N : Healthcare group Sanofi offers to buy smaller peer Kiadis for 308 mln euros	02/11/20	RE
Sanofi : Agrees to Buy Dutch Biopharmaceutical Company for EUR308 Million	02/11/20	DJ
Kiadis Pharma N : Healthcare group Sanofi offers to buy smaller peer Kiadis for 308 mln euros	02/11/20	RE
Kiadis Pharma N : Healthcare group Sanofi offers to buy smaller peer Kiadis for 308 mln euros	02/11/20	RE

Chart Kiadis Pharma N.V.

Duration

Period

More charts

Company Profile

Kiadis Pharma NV is a biopharmaceutical company based in the Netherlands. It focuses on development of therapies for patients with life-threatening diseases. Its programs consist of off-the-shelf and haploidentical donor NK-cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies. Its PM21 particle technology enables ex vivo expansion and activation of cytotoxic NK cells supporting multiple high-dose infusions. Its off-the-shelf NK-cell platform is based on NK cells from unique universal donors and can make NK-cell therapy product available for a broad patient population across a potentially wide range of indications. It develops K-NK003 for the treatment of relapse/refractory acute myeloid leukemia, and K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT. In addition, it has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors. It has offices in the United States and Europe.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+64.83%	62.59B
IQVIA HOLDINGS INC.	-2.04%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+12.98%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.88%	19.09B
BIO-TECHNE CORPORATION	+3.97%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.46%	12.26B
MEDPACE HOLDINGS, INC.	+27.32%	12.05B

Other Biotechnology & Medical Research